ACAD Stock Hits Multi-Year Highs on Impressive Data

ACAD stock

ACAD stock is the biggest biotech stock gainer in Monday’s session after ACADIA Pharmaceuticals (NASDAQ:ACAD) announced successful results in its Phase 3 clinical trial of HARMONY.

Big Relief for Investors

When a pharmaceutical company announces highly positive results from a Phase 3 trial of one of its important products, then it is a given that the stock price is going to rise and that is what happened with ACADIA Pharmaceuticals this morning. The biopharmaceutical company announced today that the Phase 3 trial of its product meant for treating dementia-related psychosis has been successful, and the product ...

Read The Full Article On StreetSignals.com

Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.

All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.